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Abstract Metastatic castration-resistant prostate cancer
(mCRPC) frequently metastasizes to the bone, often resulting
in painful skeletal events, reduced quality of life, and reduced
survival. The beta-emitting radiopharmaceuticals strontium-
89 and samarium-153 alleviated pain in mCRPC patients with
widespread skeletal metastases and have been associated with
myelotoxicity. Radium-223, a first-in-class alpha-emitting ra-
diopharmaceutical, prolonged overall survival, delayed symp-
tomatic skeletal events, and improved quality of life, versus
placebo, in patients with CRPC and symptomatic bone metas-
tases and no visceral metastases. Radium-223 provided sur-
vival benefit to patients with CRPC and symptomatic bone
metastases, regardless of prior docetaxel use. Importantly,
prostate-specific antigen level and pain palliation were not a
measure of radium-223 treatment response and should not
alter the decision to administer all six radium-223 injections,
the recommended regimen for survival benefit. Radium-223
was generally well tolerated, leading to ongoing clinical trials
in combination with other therapeutics. Thus, radium-223 is a
valuable addition to the mCRPC treatment armamentarium.
Keywords Radionuclide . Alpha emitters . Beta emitters .
Bonemetastases . Castration-resistant prostate cancer .
Radium-223 dichloride . Strontium-89 . Samarium-153 .
Abiraterone . Enzalutamide . Docetaxel . Overall survival .
Symptomatic skeletal events . Pain . Quality of life
Introduction
Most patients with metastatic prostate cancer who initially
respond to androgen deprivation therapy or surgical castration
eventually progress to castration-resistant disease [1]. As pros-
tate cancer transitions from castration sensitive to castration
resistant, the incidence of bone metastasis increases; >90 % of
patients with metastatic castration-resistant prostate cancer
(mCRPC) develop bone metastases [2]. Bone metastases dis-
rupt the homeostatic balance of bone formation and resorp-
tion, mediated by osteoblasts and osteoclasts, respectively,
impairing the structural integrity of the bone and often
resulting in skeletal events associated with increased pain,
poor quality of life (QOL), and reduced survival [3–5].
Traditionally, the treatment strategies were aimed at man-
aging pain and reducing skeletal complications by using anal-
gesics, surgery, external-beam radiation therapy (EBRT),
beta-emitting radionuclides, and bisphosphonates. The che-
motherapeutic docetaxel was the first treatment option avail-
able to improve overall survival (OS) in patients with mCRPC
[6, 7]. However, docetaxel chemotherapy is associated with
severe hematologic adverse events (AEs). Ongoing research
led to targeted therapeutics, such as the radiopharmaceutical
radium-223 dichloride (radium-223), hormonal agents
abiraterone acetate (abiraterone) and enzalutamide, and the
immunotherapeutic sipuleucel-T, that improve OS in
mCRPC patients [8].
Unlike systemic chemotherapy, bone-seeking radiopharma-
ceuticals deliver radiation directly to the bone. Available bone-
seeking radionuclide therapies for patients with bone-metastatic
prostate cancer are classified as beta-emitting radionuclides or
alpha-emitting radionuclides (Table 1). Strontium-89 and
samarium-153 are beta emitters with no proven survival benefit
as single agents inmCRPCpatients [9] and are recommended for
pain palliation in patients with mCRPC and widespread bone
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metastases [10, 11]. In contrast, radium-223, a first-in-class
alpha-emitting radiopharmaceutical, was shown in a large phase
3 randomized trial to prolong OS and improve time to the first
symptomatic skeletal event (SSE) versus placebo [12••]. This
article focuses on radium-223 and its integration into the
mCRPC treatment paradigm because it is the only radiopharma-
ceutical that confers a survival benefit in patients with CRPC and
symptomatic skeletal metastases.
Comparison of Physical Characteristics of Radionuclides:
Advantages of Alpha Versus Beta Emitters
Strontium-89 and radium-223 are deposited in the bone be-
cause of their inherent calcium-mimetic nature, whereas
samarium-153 lexidronam, also referred to as samarium-
153-ethylenediaminetetramethylenephosphonate (EDTMP),
targets the bone by chelation with EDTMP, which has a high
affinity for calcium [9]. On binding to the bone, these radio-
nuclides decay by emitting alpha or beta particles alone or
with gamma rays, which kill surrounding cells. Strontium-89
is a beta emitter, and samarium-153 predominantly emits beta
particles, whereas radium-223 predominantly emits alpha par-
ticles (Table 1). The goal of such irradiation is to kill tumor
cells in the bone while sparing the normal bone marrow, the
site of hematopoiesis; however, alpha and beta emitters are not
equal in their cell-killing ability or their impact on toxicity to
the bone marrow [9]. Ideally, radionuclides with a short tissue
range and high linear energy transfer (LET) are likely to re-
duce penetration into the bone marrow and lead to targeted
killing of tumor cells with minimal hematologic toxicity.
Additionally, a shorter half-life is also likely to reduce adverse
effects. Radium-223 meets the above criteria, and alpha parti-
cles have a relatively shorter range, spanning 2–10 cell diam-
eters with a higher LET, thereby delivering a highly targeted
effect with limited hematologic toxicity (Table 1) [13–15]. In
contrast, the beta particles emitted by strontium-89 and
samarium-153 have a longer range of 0.7 and 0.33 cm and
lower LET of 0.58 and 0.22 MeV, respectively. The unique
mechanism of action (MOA) of radium-223 underlies its effi-
cacy. Alpha particles produce cytotoxic, predominantly
nonrepairable double-stranded DNA breaks in tumor cells
[13]. A recent study conducted in an osteoblastic patient-
derived prostate cancer model suggests that radium-223 im-
pacts tumor and osteoblastic bone growth [16].
Pain Palliation With the Beta Emitters Strontium-89
and Samarium-153
Most studies with strontium-89 and samarium-153 evaluated
pain palliation and were small compared with current clinical
trial standards [9]. Additionally, the subjectivity of pain and dif-
ferences in pain measurement make it harder to compare results
across studies. A statistically significant benefit in pain palliation
with strontium-89 (150 MBq) versus the stable isotope
strontium-88was observed in a small double-blind crossover trial
involving 32 advanced prostate cancer patients [17]. Response
was assessed 5 weeks after each treatment. In this trial, 32 pa-
tients received the first injection and 16 patients received the
second injection, of whom 11 were evaluable at 5 weeks. The
mean decrease in platelets from baseline after the first strontium-
89 injection was 101×109/L, and after both injections was
104 × 109/L, whereas platelet count was not significantly
changed in patients who received placebo as the first injection
[17]. A subsequent larger, phase 3, placebo-controlled clinical
trial in eight Canadian cancer centers evaluated the efficacy of
a single 10.8 mCi injection of strontium-89 as an adjuvant to
local-field radiotherapy in hormone-refractory mCRPC patients
(n=126). This trial showed that strontium-89 treatment signifi-
cantly delayed pain progression. As expected from its physical
characteristics, hematologic toxicity involving leukocytes and
Table 1 Physical characteristics of bone-seeking radionuclides [19, 23, 38, 50, 66]












Metastron® 50.5 Beta 0.58 0.7 cm Adjunct to and as an alternative to external beam
radiotherapy for the palliation of pain from the
bone metastases secondary to prostatic carcinoma




Quadramet® 1.9 Beta 0.22 0.33 cm Pain relief in patients with confirmed osteoblastic





Xofigo® 11.4 Alpha 27.4 100 μm Treatment of patients with castration-resistant
prostate cancer, symptomatic bone metastases,
and no known visceral metastatic disease
14 Page 2 of 12 Curr Oncol Rep (2016) 18: 14
platelets was higher with the strontium-89 versus placebo group
[18]. Three patients showed clinical bleed with low platelet
counts (<50×109/L); two patients (3.6 %) in the strontium-89
group versus one patient in the placebo group (2.1 %) suffered
hemorrhage. Complete pain responses ranged 30–60 %. No sta-
tistically significant difference in survival was observed between
treatment groups. A statistically significant reduction in prostate-
specific antigen (PSA) and alkaline phosphatase (ALP) was also
observed. In 1993, the US Food andDrugAdministration (FDA)
approved the use of strontium-89 as an adjunct and alternative to
EBRT for palliation of pain from bone metastases secondary to
prostate cancer at the stage of hormone therapy failure [19, 20].
The Canadian Urological Association–Canadian Urologic
Oncology Group (CUA-CUOG) guidelines recommend the
use of strontium-89 for pain palliation of CRPC in carefully
selected patients because of the risk of prolonged
myelosuppression and transfusion dependence [21].
A pivotal phase 3 trial (n=152) comparing nonradioactive
samarium-152 versus radioactive samarium-153 lexidronam
complexes in patients with hormone-refractory prostate can-
cer and painful bone metastases showed that samarium-153
lexidronam 1mCi/kg was safe and effective for pain palliation
[22]. In that trial, pain intensity was measured using the linear
100-mm visual analog scale and nonlinear pain descriptor
scales; a statistically significant reduction in opioid use, sug-
gesting pain reduction, was observed at treatment weeks 3 and
4. Incidence of grade 4 hemoglobin level was 2 % in
samarium-152-treated versus 1 % in samarium-153-treated
patients; incidences of grade 4 platelet level and grade 4 white
blood cell level were 0 % in both groups. Samarium-153 was
approved for pain palliation in patients with confirmed osteo-
blastic metastatic bone lesions and is used in prostate cancer
patients with painful bone metastases [23].
A recent systematic review andmeta-analysis of clinical stud-
ies involving strontium-89 and samarium-153 showed overall
efficacy of 70 % for both agents in alleviating metastatic bone
pain in mCRPC patients and complete pain relief in 27 % of
patients [24]. Dose-response studies showed increasing rates of
response to pain and increasing myelotoxicity with increasing
doses of samarium-153, limiting the use of higher doses [25].
In contrast, radium-223 showed increasing pain response with
increasing doses, without obvious differences in hematologic
toxicities at different doses [26].
Pain recurrence is common among mCRPC patients with
skeletal metastases. Therefore, repeated administration of
strontium-89 and samarium-153 has been investigated for
sustained pain relief. Repeated samarium-153 administration
at 1 mCi/kg in a trial involving 202 cancer patients receiving
two or more doses showed reversible hematologic adverse
effects and effective pain palliation; platelet and leukocyte
counts returned to baseline levels by week 8 in 90 % of pa-
tients, and pain scores decreased significantly at week 4 after
each of the first three doses [27]. Repeated strontium-89
administration in cancer patients with painful skeletal metas-
tases was also safe and effective [28]. However, so far, there is
no conclusive evidence supporting a survival benefit with the
beta emitters strontium-89 and samarium-153 when used as
single agents in mCRPC patients.
Beta Emitters With Prior or in Combination With
Chemotherapy or EBRT
To improve the effectiveness of strontium-89 and samarium-
153, combinations with chemotherapeutics and EBRT have
been studied. In the TRAPEZE phase 2/3 trial in 757
mCRPC patients, strontium-89 treatment after 6 cycles of do-
cetaxel improved clinical progression-free survival (HR 0.85;
95 % CI 0.72–0.99; p=0.036) [29]. A smaller phase 2 trial
involving 72 mCRPC patients, who had previous induction
chemotherapy and were subsequently randomized to doxoru-
bicin alone (median survival 16.8 months) or combined with
strontium-89 (median survival 27.7 months), showed a sur-
vival benefit of 10.9 months in patients treated with the com-
bination (HR 2.76; 95 % CI 1.44–5.29) [30]. A subsequent
phase 2 trial of a combination of strontium-89 with alternating
chemotherapeutics and hormonal therapeutics in advanced
hormone-independent prostate cancer patients also showed a
benefit of strontium-89 in progression-free survival and OS
[31]. A phase 2 trial of a consolidation regimen of samarium-
153-EDTMP with docetaxel in mCRPC patients, who had
previously responded or stabilized after docetaxel and hor-
monal therapy, showed that the combination was well tolerat-
ed and produced sustained pain relief and a PSA response
[32]. Samarium-153 was safely used in prostate cancer pa-
tients who had prior chemotherapy or radiotherapy [33].
A recent trial of 177 mCRPC patients with multiple painful
bone metastases showed that samarium-153, combined with lo-
cal EBRT versus samarium-153 alone, improved pain palliation
without significantly increasing hematologic and overall toxicity
[34]. The concurrent use of strontium-89 with EBRTwas effec-
tive and safe in a recent retrospective analysis [35]. The National
Comprehensive Cancer Network (NCCN) Clinical Practice
Guidelines in Oncology recommend strontium-89 or
samarium-153 with or without focal EBRT for pain palliation
in patients with widespread bone metastases.
Improving Survival in Metastatic CRPC With
Radium-223
Promising results from previous phase 1 and 2 studies show-
ing a favorable safety profile and survival benefit of radium-
223 treatment in mCRPC patients led to a phase 3 trial,
Alpharadin in Symptomatic Prostate Cancer (ALSYMPCA)
[36, 37]. This phase 3, randomized, double-blind, multination-
al trial compared efficacy and safety of radium-223 versus
placebo in CRPC patients with symptomatic bone metastases
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[12••]. The trial enrolled 921 patients with histologically con-
firmed, progressive CRPC with two or more bone metastases
and no known visceral metastases, who received docetaxel or
were not healthy enough or declined docetaxel. Patients were
required to have regular use of analgesic medication or treat-
ment with EBRT for palliation of cancer-related bone pain
within the previous 12 weeks. Patients were randomized 2:1
to receive six injections at 4-week intervals of either radium-
223 (intravenous injection of 50 kBq per kilogram of body
weight) or placebo; both groups received best standard of care
(BSOC). Prior to randomization, patients were stratified by
previous use of docetaxel (yes or no), baseline ALP level
(<220 U/L vs. ≥220 U/L), and the current use of a bisphos-
phonate (yes or no) [12••]. The planned follow-up period was
3 years after each patient’s first injection [12••].
Efficacy: OS
The primary efficacy end point of ALSYMPCA was OS; the
secondary end points included time to first SSE, change in
PSA and ALP levels, and quality of life (QOL) [12••]. In the
final analysis involving 921 patients, radium-223 prolonged me-
dian survival by 3.6 months (median survival, 14.9 vs.
11.3 months; HR 0.70; 95 % CI 0.58–0.83; p<0.001). The
radium-223 survival benefit was consistent across patient sub-
groups classified based on ALP levels, bisphosphonate use, opi-
oid use, Eastern Cooperative Oncology Group performance sta-
tus, prior docetaxel use or nonuse, and extent of metastases
[12••]. ALSYMPCA results led to regulatory approval of
radium-223 in CRPC with symptomatic skeletal metastases and
no visceral metastases; the recommended treatment regimen to
achieve OS benefit is six injections of radium-223 50 kBq
(1.35 μCi) per kilogram of body weight, administered intrave-
nously at 4-week intervals [10, 11, 20, 21, 38–40]. Radium-223
represents an important advancement, as the only radiopharma-
ceutical agent that improves OS in mCRPC patients.
Efficacy: SSE
In the clinical trials of therapeutics in mCRPC patients per-
formed before ALSYMPCA, skeletal complications were de-
scribed as skeletal-related events (SREs), which were monitored
through periodic radiologic review. SREs included pathologic
fracture and spinal cord compression (both determined by serial
radiologic review), radiation therapy or surgery to the bone, and
change in antineoplastic therapy to treat bone pain [41, 42]. As a
secondary end point, ALSYMPCA used a more clinically rele-
vant end point based on clinical manifestation, rather than serial
radiologic review, and included time to the first symptomatic
skeletal event (SSE), defined as use of EBRT to relieve bone
pain, occurrence of a new symptomatic pathologic fracture, spi-
nal cord compression, or tumor-related orthopedic surgical in-
tervention. Importantly, radium-223 increased the median time
to first SSE by 5.8 months compared with placebo (median
15.6 months vs. 9.8 months; HR 0.66; 95 % CI 0.52–0.83;
p=0.00037) [43•]. Additionally, radium-223 significantly re-
duced the risk of requiring EBRT for bone pain (HR 0.67;
95 % CI 0.53–0.85; p=0.001) and the risk of spinal cord com-
pression (HR 0.52; 95%CI 0.29–0.93; p=0.03) compared with
placebo. Although not statistically significant, a trend toward the
reduction of the risk of symptomatic pathologic bone fracture
(HR 0.62; 95 % CI 0.35–1.09; p=0.10) or the need for tumor-
related orthopedic surgery (HR 0.72; 95 % CI 0.28–1.82;
p=0.48) was observed. Prespecified analyses of subgroups by
baseline total ALP, previous docetaxel use, and current bisphos-
phonate use also showed a consistent trend favoring radium-223
treatment [43•].
Efficacy: Biochemical Markers
Radium-223 MOA suggests a primary pharmacodynamic ef-
fect on serum total ALP (tALP) rather than PSA, unlike hor-
monal agents targeting the androgen receptor (AR) axis for
which PSA level can indicate therapeutic effect. Moreover,
ALP has been found to be a more clinically relevant marker
than PSA for bone metastasis in prostate cancer [44, 45].
Consistently, in ALSYMPCA, radium-223 treatment versus
placebo led to a significantly greater proportion of patients
with a decrease of at least 30 % in tALP (radium-223, 47 %;
placebo, 3 %; p<0.001) [12••]. Exploratory post hoc analyses
of tALP in the 3-year follow-up of ALSYMPCA patients
showed that radium-223 treatment led to a rapid and sustained
decrease in tALP, which correlated with OS [46]. In
ALSYMPCA, radium-223 treatment led to a significant in-
crease in the median time to increase in PSA level (HR 0.64;
95 % CI 0.54–0.77; p<0.001) [12••]. Although encouraging,
these results of tALP and PSA dynamics in radium-223-
treated patients need validation in additional clinical studies.
Identification of biomarkers of radium-223 efficacy remains a
pressing clinical need.
Efficacy: QOL and Effect on Bone Pain
Radium-223 treatment led to a clinically meaningful improve-
ment in QOL versus placebo, as measured by Functional
Assessment of Cancer Therapy—Prostate (FACT-P) score
during the treatment period (25 vs. 16 %; p=0.02; mean
change from baseline to week 16, −2.7 vs. −6.8; p=0.006)
in ALSYMPCA [12••]. In a post hoc analysis, assessment of
the effect of radium-223 on health-related QOL, measured
by EuroQol 5D (EQ-5D) utility scores, demonstrated the
greatest treatment benefit in stable disease (disease progres-
sion measured by PSA and ALP levels), prior to an SSE [47].
In conjunction with the effect of radium-223 in delaying
SSEs, these results suggest the importance of earlier use of
radium-223 in disease progression to prevent SSEs, which can
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result in decreased QOL. Post hoc analyses of ALSYMPCA
FACT-P scores showed that radium-223 treatment was asso-
ciated with greater odds of pain relief versus placebo at weeks
16 and 24 of treatment (odds ratio 2.58; 95 % CI 1.18–5.62;
p=0.018) [48]. However, pain response was not observed in
all patients receiving radium-223 [48]. An ongoing phase 2
trial is assessing radium-223 efficacy in pain palliation
(Table 2, NCT02278055) [49]. Thus, pain alleviation should
not be used as a measure of radium-223 efficacy to guide
treatment continuation. Instead, adding BSOC, such as anal-
gesics, for pain management should be considered while con-
tinuing radium-223 treatment to ensure that patients receive
all six radium-223 injections, the recommended course to
achieve OS benefit [38].
Safety
Of 921 patients randomized in ALSYMPCA, 901 were in-
cluded in the safety population. Radium-223 safety was pre-
viously reviewed in detail for the overall ALSYMPCA popu-
lation and in patient subgroups (prior docetaxel, concomitant
EBRT, baseline opioid use [yes/no]) [50]. Radium-223 was
well tolerated with no clinically meaningful differences in
incidence of hematologic AEs between trial groups; grade 3
febrile neutropenia occurred in one patient (<1 %) in each
group and grade 5 thrombocytopenia in one patient in the
radium-223 group, without evidence of bleeding [12••].
Additionally, chemotherapy after radium-223 treatment ap-
peared to be well tolerated [51, 52].
Radium-223 remained safe and well tolerated and showed
no new safety concerns during the 3-year follow-up period
[53]. The favorable safety profile of radium-223 observed in
ALSYMPCA led to the ongoing international, prospective,
observational, cohort trial to evaluate the long-term safety
profile of radium-223 in a real-world setting in more diverse
CRPC patients with bone metastases (REASSURE). Patients
will be followed until 7 years after the last radium-223 dose,
and the decision to treat with radium-223 will be independent
from and before enrollment in the trial (Table 2,
NCT02141438).
Integration of Radium-223 in the Management of Patients
With Metastatic CRPC
Therapeutic options for mCRPC are rapidly growing, and, in
addition to radium-223, a number of therapies that prolong sur-
vival have been added to the mCRPC treatment armamentarium.
The optimal use of radium-223 in managing this disease requires
determining the sequencing and combination of these agents.
Results of studies addressing the integration of radium-223 rela-
tive to docetaxel and hormonal agents are discussed here, with a
mention of ongoing radium-223 clinical trials.
Sequencing of Therapeutics: Radium-223 With Concurrent
EBRT
ALSYMPCA involved patients who are already receiving
EBRT for bone pain at trial entry as well as those who re-
ceived EBRT during the trial, as part of BSOC. A post hoc
analysis evaluated the safety of concomitant EBRT with
radium-223 and the effect of radium-223 on the requirement
of EBRT for bone pain relief [54]. The hematologic safety
profile of radium-223 with concomitant EBRT was similar
to that without concomitant EBRT, providing the additional
option of EBRT for pain during radium-223 treatment.
Radium-223 in Patients With Prior Docetaxel
At the initiation of the ALSYMPCA trial, docetaxel was the only
available drug that improved survival of mCRPC patients;
ALSYMPCA included patients both with and without prior do-
cetaxel therapy. A prespecified subgroup analysis investigated
radium-223 efficacy and safety by prior docetaxel use [55•]. Of
the 921 randomized patients, 526 (57 %) had prior docetaxel
(radium-223, 352; placebo, 174) and 395 (43 %) had no prior
docetaxel (radium-223, 262; placebo, 133). Radium-223
prolonged median survival versus placebo, regardless of prior
docetaxel use (prior docetaxel use, HR 0.70; 95 % CI 0.56–
0.88; p=0.002) or nonuse (no prior docetaxel use, HR 0.69;
0.52–0.92; p=0.01) [55•]. Consistent with the known hemato-
logic toxicity of docetaxel, patients who received prior docetaxel
had a higher incidence of thrombocytopenia with radium-223
than with placebo (9 vs. 3 %), whereas among patients without
prior docetaxel, the incidence of thrombocytopenia was similar
between groups (radium, 3 %; placebo, 1 %). Overall, radium-
223 improved OS and had a favorable safety profile with a low
incidence ofmyelosuppression irrespective of previous docetaxel
use, leading to clinical practice guideline recommendations for
the use of radium-223 in mCRPC regardless of prior docetaxel
use [10, 39]. Thus, radium-223 is a new treatment option for
mCRPC patients who previously received docetaxel as well as
those who are not healthy enough to tolerate docetaxel therapy.
Chemotherapy Post Radium-223
A post hoc analysis evaluated safety and OS in a subset of
ALSYMPCA patients (radium-223, 142; placebo, 64) who re-
ceived chemotherapy following treatment with radium-223 or
placebo. There were no detrimental effects on OS and no new
hematologic safety concerns, suggesting that chemotherapy may
be given safely following treatment with radium-223 [56].
Radium-223 With Concurrent Docetaxel
Preliminary findings from a phase 1/2a trial (N=46) comparing
radium-223 combined with docetaxel versus docetaxel alone in
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Table 2 Currently ongoing clinical trials of radium-223 in metastatic prostate cancer [49]




NCT02278055 A phase 2, open-label, nonrandomized trial to assess
pain efficacy with radium-223 in symptomatic
mCRPC within 12 weeks of treatment
Primary: pain response




NCT02023697 A three-arm, randomized, open-label phase 2 trial of
radium-223 dichloride 50 vs. 80 kBq/kg, and vs.
50 kBq/kg in an extended dosing schedule in
CRPC patients with bone metastasis
Primary: SSE-free survival
Secondary: OS, time to first SSE, rPFS, time to
radiologic progression, pain improvement rate,
time to pain progression, number of patients with
TEAEs or SAEs, change in 24-h analgesic use
March 2014, October
2018, 389
NCT02346526 A single-arm, open-label, phase 2 biomarker trial of
radium-223 in mCRPC patients
Primary: change from baseline in bone scan index at
2 months
Secondary: mean percentage change in bone lesion
area by 18-month survival status, changes in CTC
number, circulating biomarkers of tumor
microenvironment, changes in CTC number and
translational biomarkers
May 2015, July 2021, 22
NCT02204943 An interventional, open-label pharmacodynamic trial
of radium-223 in CRPC patients with bone
metastases
Primary: change in proportion of patients who
overexpress ALP in bone metastases
Secondary: change in biomarkers of epithelial
plasticity and osteomimicry expressed in the





An observational trial in the routine clinical practice
setting to evaluate the short- and long-term safety
of radium-223 in mCRPC patients and to evaluate
the risk of developing second primary cancers
Primary: incidence of developing second primary
malignancies, incidence of treatment-emergent
SAEs, incidence of drug-related TEAE, incidence
of drug-related SAEs, bone marrow suppression
Secondary: OS, the worst pain score and pain
interference score over time as determined by




NCT02034552 A randomized, open-label, phase 2a trial evaluating
quantified bone scan response following treatment
with radium-223 alone or in combination with
abiraterone acetate or enzalutamide in CRPC
patients with bone metastases
Primary: patient bone scan response
Secondary: rPFS, SSE-FS, time to first SSE, OS, time
to radiologic bone progression by treatment group,




NCT02463799 A phase 2, randomized of sipuleucel-T with or without
radium-223 in men with asymptomatic or
minimally symptomatic bone-metastatic CRPC
Primary: immune response to treatment with
sipuleucel-T (with or without radium-223)
measured by peripheral PA2024 T-cell proliferation
Secondary: peripheral antigen-specific T-cell
proliferation over time, peripheral antigen-specific
T-cell activation to sipuleucel-T over time, antigen-
specific antibody response to sipuleucel-T over
time, sipuleucel-T-induced antigen spread (epitope
spread) phenomena, the sipuleucel-T product
immune parameters, safety of combined use of
radium-223 and sipuleucel-T, time to PSA
progression, time to ALP progression, time to pain
progression and first cancer- related opioid use,
time to radiographic or clinical progression, time to





A randomized, phase 3, double-blind, placebo-
controlled trial of radium-223 dichloride in
combination with abiraterone acetate and
prednisone/prednisolone in the treatment of
asymptomatic or mildly symptomatic
chemotherapy-naïve subjects with bone
predominant mCRPC
Primary: SSE-free survival
Secondary: OS, time to opiate use for cancer pain,
time to pain progression, time to cytotoxic





An observational, prospective, single-arm cohort trial
for pain evaluation in radium-223-treated patients
with bone metastases
Primary: pain response
Secondary: change of pain over time, change in bone-
pain related QOL, pain control rate, pain
progression rate, time to first pain progression, time
to first opioid use, summary of evaluation of
covariates on pain response, relation between bone
uptake in known lesions and pain palliation, dosage
March 2015, September
2017, 300
14 Page 6 of 12 Curr Oncol Rep (2016) 18: 14
Table 2 (continued)




of radium-223, number of injections of radium-
223, course of blood count, number of patients with
TEAE, time to next tumor treatment, time to first
SSE, OS
NCT01810770 An interventional, phase 3, single-arm, international,
open-label, prospective trial to evaluate safety and
efficacy of radium-223 dichloride in an Asian
population with CRPC metastatic to the bone
Primary: number of patients with AEs, number of
patients with laboratory changes, number of
patients with changes in vital signs, number of
patients with changes in ECG, OS
Secondary: changes in total ALP, number of patients
with total ALP normalization, time to total ALP
progression, changes in PSA, time to PSA
progression, time to first SRE, SRE-free survival,
time to first SRE, time to occurrence of first use of
radio-isotopes to relieve skeletal symptoms, time to
occurrence of first start of any other anticancer
treatment, time to occurrence of first deterioration
of ECOG performance status, QOL
March 2013, September
2016, 234
NCT02331303 An observational trial to evaluate the extent of
potential off-label use of radium-223 (Xofigo®) in
Sweden
Primary: proportion of men with mCRPC of radium-
223 use, proportion of being women of radium-223
use, proportion of being children of radium-223
use, proportion of bone metastasis but having a
diagnosis other than mCRPC, dosage of radium-
223, proportion of patients of dose outside label
recommendation




An observational, prospective, single-arm cohort trial to
assess OS, SSE-free survival, and QOL of
chemo-naïve mCRPC patients receiving radium-
223 under real-life conditions in Germany
Primary: OS
Secondary: evaluation of covariates on OS in mCRPC
patients, SSE-FS, covariates on SSE-FS, time to
next tumor treatments, incidence of TEAE, QOL,








A randomized, multicenter phase 3 trial comparing
enzalutamide vs. a combination of radium-223 and
enzalutamide in asymptomatic or mildly
symptomatic CRPC with metastasis to bone
Primary: rPFS
Secondary: OS, prostate cancer-specific survival, first
SSE, time and incidence of first skeletal
progression-free, time from entry to initiation of
next systemic therapy, treatments elected after first
disease progression, second progression-free
survival in sequential regimen, pain, time to pain







A phase 1/1b trial of radium-223 in combination with
tasquinimod for CRPC patients with bone
metastases
Note: Active Biotech and Ipsen have decided to
discontinue development of tasquinimod in
prostate cancer (press release 4-16-15)
Primary: safety of combining radium-223 with
tasquinimod
Secondary: bone ALP response, time to radiographic
or clinical progression or death, time to first
symptomatic SRE, proportion of patients without
symptomatic progression at 6 months, median
change in bone scan index (BSI) within patients at
12 weeks compared to baseline bone scan, PSA
progression, time to death after start of trial
treatment, changes in bone markers





A pilot trial to define the relevant immune checkpoints
expressed on metastatic prostate cancer circulating
tumor cells (CTC)
Primary: percent expression of immune checkpoint
markers on CTCs
Secondary: changing prevalence of immune
checkpoint biomarkers on CTCs over time in a
longitudinal analysis of four different populations
of men with metastatic prostate cancer, change over
time in mutational profiles, androgen receptor
variant expression, and immune- and tumor-related
RNA signatures in CTC-enriched blood,
expression of PD-L1, PD-L2, B7-H3, and CTLA-4
in metastatic tumor tissue obtained by elective CT
or ultrasound-guided research biopsies in up to 10
patients and compare this expression percentage
with CTC immune checkpoint expression
October 2015, January
2017, 40
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mCRPC patients showed that the combinationwas well tolerated
[57]. The trial regimen was 5 intravenous injections of radium-
223 (50 kBq/kg), 1 injection every 6 weeks, and 10 intravenous
infusions of docetaxel (60 mg/m2), once every 3 weeks [57].
Phase 1 results concluded that it was safe to proceed to the
expanded phase 2a safety cohort. Preliminary phase 2a results
showed that the combination of radium-223 and docetaxel
remained safe and well tolerated, and levels of bone ALP and
PSA decreased in both treatment arms. Intriguingly, a higher
percentage of patients receiving the radium-223 and docetaxel
regimen versus docetaxel alone had normalized bone ALP levels
[57]. Larger studies are needed to discern the clinical benefit of
such changes in serum markers.
Radium-223 With Concurrent Hormonal Therapies
CRPC is now known to be driven by AR signaling [58, 59].
Two agents targeting the androgen axis have been investigated
in mCRPC: abiraterone and enzalutamide. In a pivotal, ran-
domized, placebo-controlled phase 3 trial (COU-AA-301),
abiraterone with prednisone significantly improved survival
(14.8 vs. 10.9 months; p<0.001) in mCRPC patients who
had previously received docetaxel. Abiraterone was approved
by the FDA in the post-docetaxel setting in April 2011 [10, 20,
60]. A phase 3 trial (COU-AA-302) of abiraterone in the pre-
docetaxel setting resulted in its FDA approval in chemothera-
py-naïvemCRPC patients [10, 20, 61]. Enzalutamide improved
OS (18.4 vs. 13.6 months; p<0.001) of mCRPC patients who
had previously received docetaxel in a randomized, placebo-
controlled phase 3 trial (AFFIRM), leading to its FDA approval
in 2012 for treating mCRPC in docetaxel-treated patients [62].
Enzalutamide reduced the risk of death by 29 % versus placebo
in chemotherapy-naïve patients (HR 0.71; 95 % CI 0.60–0.84;
p<0.001), leading to extension of its FDA approval to these
patients [63]. These agents’ availability and their complemen-
tary MOAs suggested a potential added clinical benefit by
combining them with radium-223. Importantly, abiraterone,
enzalutamide, and radium-223 have non-overlapping toxicities,
further reducing the possibility of serious treatment-emergent
adverse events (TEAEs) resulting from the combination.
Prior to the May 2013 FDA approval of radium-223, a
phase 2, prospective, interventional, open-label, multicenter
US expanded access program (EAP) trial was conducted in
the USA, providing early access of radium-223 to mCRPC
patients with symptomatic metastases and assessing acute
and long-term safety of radium-223 [64]. One hundred
eighty-four patients with symptomatic, progressive, bone-
predominant mCRPC and no visceral metastases, who either
received or were not eligible for docetaxel, received
abiraterone and enzalutamide prior to the start of, during,
and following the radium-223 treatment period. Primary end
points included safety in the acute period (up to 30 days post-
treatment) and long-term treatment period (≥30 days posttreat-
ment through follow-up); other and exploratory end points
were OS, time to first SSE, and changes in ALP and PSA
levels. This trial was terminated early following radium-223
regulatory approval, resulting in a limited follow-up period of
approximately 3 to 9 months [64].
Patient demographics and baseline characteristics were
generally similar in the ALSYMPCA and US EAP trials, ex-
cept for total ALP and PSA levels and median time from
diagnosis, which were longer in EAP patients [64]. The inci-
dences of grades 3 to 5 TEAEs were similar in the
ALSYMPCA and US EAP trials, as were the incidences of
hematologic AEs. No secondary malignancies in either trial
were attributed to radium-223 [64]. Patient censoring and the
short follow-up period did not allow estimation of OS of all
patient subgroups; patients treated concurrently with radium-
223 and abiraterone/enzalutamide (n=17) (without prior treat-
ment with abiraterone/enzalutamide) appeared to survive lon-
ger than those who had not received concurrent hormonal
therapy with radium-223 (n=167) [51].
Table 2 (continued)







A phase 2, interventional trial to determine the safety
and tolerability of radium-223 administered in
combination with enzalutamide in progressive
mCRPC
Primary: determine safety
Secondary: time to clinical and PSA progression, PSA




Data from Clinicaltrials.gov database accessed on September 27–28, 2015
AEs adverse events, ALP alkaline phosphatase, BSI bone scan index, CRPC castration-resistant prostate cancer, CT computed tomography, CTC
circulating tumor cell, mCRPC metastatic castration-resistant prostate cancer, OS overall survival, PSA prostate-specific antigen, QOL quality of life,
rPFS radiologic progression-free survival, SAEs serious adverse events, SRE skeletal related event, SSE symptomatic skeletal event, SSE-FS symptom-
atic skeletal event-free survival, TEAEs treatment-emergent adverse events
a Estimated study completion date is the final data collection date for the primary end point
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In the phase 3b international EAP trial, the efficacy and
safety of concomitant treatment with abiraterone/
enzalutamide and radium-223 were evaluated in 696 patients
from 14 countries; 154 (22 %) received concomitant
abiraterone, 50 (7 %) enzalutamide, and 15 (2 %) abiraterone
and enzalutamide; 277 (40 %) had prior abiraterone, and 56
(8 %) prior enzalutamide [65]. Baseline characteristics were
generally comparable between patients receiving radium-223
alone versus radium-223 with concomitant abiraterone/
enzalutamide; median PSA (164.2 vs. 98.9 μg/L) and ALP
(161.0 vs. 142 U/L) levels were higher in the former group.
Patients receiving radium-223 with concomitant abiraterone/
enzalutamide appeared to survive longer than those receiving
radium-223 alone. The safety profiles of radium-223 with or
without concomitant abiraterone/enzalutamide were similar
[65]. A randomized phase 3 trial is under way to confirm these
results [65].
With the availability of new agents to improve survival in
mCRPC, there is a growing need for data to guide patient
selection, choice of combinations, and sequence of adminis-
tration of these drugs for optimal disease management.
Currently ongoing studies with radium-223 are aimed at fill-
ing some of these data gaps (Table 2). A randomized, double-
blind, placebo-controlled phase 3 trial (ERA223) is currently
under way to evaluate the safety and efficacy of radium-223
with abiraterone and prednisone versus abiraterone and pred-
nisone alone in chemotherapy-naïve CRPC patients with me-
tastasis to the bone (Table 2, NCT02043678). It is noteworthy
that this trial involves patients who are chemotherapy-naïve
and have asymptomatic or mildly symptomatic mCRPC with
bone metastases, a population in which radium-223 has not
been used previously. A combination of radium-223 with
enzalutamide is currently being tested in asymptomatic or
mildly symptomatic CRPC patients with metastases to the
bone (Table 2, NCT02194842). Additionally, a combination
of radium-223 with the immunotherapeutic sipuleucel-T,
which is approved for asymptomatic or minimally symptom-
atic CRPCwith bonemetastases, is being investigated in these
patients (Table 2, NCT02463799).
Conclusions and Future Directions
The beta emitters strontium-89 and samarium-153 did not pro-
long survival when used as single agents and are recommend-
ed solely for pain palliation in mCRPC. The alpha emitter
radium-223 improved OS, delayed SSEs, preserved QOL,
and was well tolerated in patients with CRPC and symptom-
atic skeletal metastases. Notably, radium-223 is approved for
use in both pre-docetaxel and post-docetaxel clinical settings,
with a recommended treatment regimen of 6 cycles.
Identification of biomarkers of radium-223 efficacy may op-
timize disease management, while ongoing clinical studies
may clarify treatment sequencing strategies.
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